Press releases | WebDisclosure

Basculer en Français

10964	Companies
239975	Keywords
168746	Articles
129114	Press releases

Home
Press releases

PRESS RELEASE

published on 02/25/2026 at 08:30, 6 months 14 days ago

cyan AG enters into partnership with CANCOM: cyan Guard 360 now available on the CANCOM Cloud Marketplace
cyan AG partners with CANCOM to offer cyan Guard 360 on CANCOM Cloud Marketplace, enhancing cybersecurity services for ISPs and SMEs. The EU-hosted solution provides efficient protection with minimal costs

Cybersecurity Partnership Cyan AG CANCOM Cloud Marketplace
PRESS RELEASE

published on 02/25/2026 at 08:29, 6 months 14 days ago

From deal to discovery: Gold Hunter now focusing on Great Northern project after CAD 48 million success!
Gold Hunter Resources shifts focus to Great Northern project post CAD 48 million success, implementing district consolidation strategy. Evidence of value creation and strategic management

Great Northern Project Value Creation Strategic Management District Consolidation Gold Hunter Resources
PRESS RELEASE

published on 02/25/2026 at 08:05, 6 months 14 days ago

Tocvan Builds Momentum at Gran Pilar: Six Exploration Holes Drilled, Drone Mag Survey and Water Monitoring Wells for Pilot Completed
Tocvan Ventures Corp. updates active exploration drilling program at Gran Pilar Gold-Silver Project in Sonora, Mexico. High-potential targets and efficient operations highlighted

Exploration Drilling Tocvan Ventures Corp. Gold-silver Project Sonora Mexico Gran Pilar
PRESS RELEASE

published on 02/25/2026 at 08:00, 6 months 14 days ago

Transaction in Own Shares
Molten Ventures Plc (LSE: GROW) announces share repurchase details with Deutsche Bank. Total shares purchased: 25,000; Highest price: 457.20p; Lowest price: 440.80p

Share Repurchase Molten Ventures Plc LSE GROW Deutsche Bank
PRESS RELEASE

published on 02/25/2026 at 08:00, 6 months 14 days ago

Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
Pentixapharm receives FDA approval for dual theranostic INDs in hemato-oncology program, targeting AML and MM with CXCR4-directed radiotherapy

FDA Approval Pentixapharm CXCR4 Dual Theranostic Hemato-oncology Program
PRESS RELEASE

published on 02/25/2026 at 08:00, 6 months 14 days ago

JOST Werke SE: JOST determines number of new shares and placement price
JOST Werke SE increases share capital by placing 1,490,000 new shares with institutional investors at EUR 62.13 per share, raising approximately EUR 93 million

Institutional Investors Share Capital Increase JOST Werke SE Financial Flexibility Placement Price
PRESS RELEASE

published on 02/25/2026 at 08:00, 6 months 14 days ago

Touchstone Exploration Announces 2025 Year-End Reserves
Touchstone Exploration Inc. announces 2025 year-end reserves with an increase in PDP reserves and NPV10 values. Operational highlights include facility optimization and successful drilling at Cascadura-5 and Carapal Ridge-3

Touchstone Exploration Inc. Operational Highlights Cascadura-5 Drilling 2025 Year-end Reserves NPV10 Values
PRESS RELEASE

published on 02/25/2026 at 08:00, 6 months 14 days ago

Résiliation du contrat de liquidité confié à TSAF en raison d'une liquidité suffisante du marché
CRYPTO BLOCKCHAIN INDUSTRIES résilie contrat de liquidité avec TSAF sur Euronext Growth Paris en raison de suffisante liquidité du titre sur le marché

Euronext Growth Paris Contrat De Liquidité Liquidité TSAF Crypto Blockchain Industries
PRESS RELEASE

published on 02/25/2026 at 07:33, 6 months 14 days ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3Y - Change of Directors' Interest Notice
Dexus Finance Pty Limited releases Appendix 3Y - Change of Directors' Interest Notice for Varya Davidson. Find more details on Dexus's ASX release at www.dexus.com/dxs

Dexus Finance Pty Limited ASX Release Appendix 3Y Varya Davidson Change Of Directors' Interest Notice
PRESS RELEASE

published on 02/25/2026 at 07:30, 6 months 14 days ago

BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
BRAIN Biotech's Q1 25/26 results show revenue decline but improved EBITDA. Breakthrough Aurase Wound Gel by SolasCure for chronic wounds. BRAIN BioIncubator segment thrives

EBITDA BRAIN Biotech Q1 Results SolasCure Aurase Wound Gel

Accesswire

Published on 09/11/2026 at 04:00, 4 hours 47 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 10 hours 22 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 15 hours 1 minute ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 17 hours 27 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 17 hours 47 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 08:15, 32 minutes ago

EQS-Adhoc: Airbus SE: Airbus commences limited share buyback to support future employee share ownership plan activities and equity-based compensation
Published on 09/11/2026 at 08:02, 45 minutes ago

PUMA CCO Matthias Baeumer to step down from Management Board
Published on 09/11/2026 at 08:00, 47 minutes ago

Cairn Homes Plc: Transaction in Own Shares
Published on 09/11/2026 at 07:30, 1 hour 17 minutes ago

NAGRAVISION and MediaTek Broaden Partnership to Redefine Content Security for Premium Content on Connected TVs
Published on 09/11/2026 at 00:05, 8 hours 42 minutes ago

Club Offers for Travel Enthusiasts in Germany

Les Echos

Published on 09/11/2026 at 07:00, 1 hour 47 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 hour 47 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 hour 47 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 hour 47 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 13 hours 17 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE